Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – What’s Next?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) shares gapped down before the market opened on Tuesday . The stock had previously closed at $25.94, but opened at $25.10. Chugai Pharmaceutical shares last traded at $26.33, with a volume of 2,285 shares.

Chugai Pharmaceutical Stock Performance

The company has a 50 day moving average of $24.24 and a 200 day moving average of $24.07. The firm has a market cap of $89.06 billion, a P/E ratio of 33.83 and a beta of 0.63.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Friday, October 24th. The company reported $0.23 earnings per share for the quarter. The firm had revenue of $2.26 billion for the quarter. Chugai Pharmaceutical had a net margin of 32.74% and a return on equity of 20.63%. As a group, analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.